The authors thank Winona Wright for study coordination and technical assistance with this article; the NIH-supported Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer for helpful suggestions and ancillary study status; and the PanCAN Early Detection Initiative participants and investigators for their important contributions to the development of effective pancreatic cancer screening strategies.
Howlader N, Noone A, Krapcho M, et al, eds. SEER cancer statistics review, 1975–2017. Accessed December 23, 2020. Available at: https://seer.cancer.gov/csr/1975_2017/
Katz MHG, Hu CY, Fleming JB, et al. Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer. Arch Surg 2012;147:513–519.
Pannala R, Basu A, Petersen GM, et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009;10:88–95.
Chari ST, Leibson CL, Rabe KG, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005;129:504–511.
Sharma A, Kandlakunta H, Nagpal SJS, et al. Model to determine risk of pancreatic cancer in patients with new-onset diabetes. Gastroenterology 2018;155:730–739.e3.
Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 2016;316:1093–1103.
Rocca WA, Yawn BP, St Sauver JL, et al. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc 2012;87:1202–1213.
Maitra A, Sharma A, Brand RE, et al. A prospective study to establish a new-onset diabetes cohort: from the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas 2018;47:1244–1248.
Wright AK, Kontopantelis E, Emsley R, et al. Life expectancy and cause-specific mortality in type 2 diabetes: a population-based cohort study quantifying relationships in ethnic subgroups. Diabetes Care 2017;40:338–345.
Billings BJ, Christein JD, Harmsen WS, et al. Quality-of-life after total pancreatectomy: is it really that bad on long-term follow-up? J Gastrointest Surg 2005;9:1059–1067.
Corral JE, Das A, Bruno MJ, et al. Cost-effectiveness of pancreatic cancer surveillance in high-risk individuals: an economic analysis. Pancreas 2019;48:526–536.
Bonomi AE, Boudreau DM, Fishman PA, et al. Quality of life valuations of mammography screening. Qual Life Res 2008;17:801–814.
Choi JG, Nipp RD, Tramontano A, et al. Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: results of a decision analysis. Oncologist 2019;24:945–954.
Meng Y, McCarthy G, Berthon A, et al. Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours—an analysis based on the CLARINET study. Health Qual Life Outcomes 2017;15:131.
Centers for Medicare & Medicaid Services. Physician fee schedule search. Accessed December 23, 2020. Available at: https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx
Tramontano AC, Chen Y, Watson TR, et al. Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013. Medicine (Baltimore) 2019;98:e18082.
Li R, Bilik D, Brown MB, et al. Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care 2013;19:421–430.
Bhulani N, Gupta A, Gao A, et al. Palliative care and end-of-life health care utilization in elderly patients with pancreatic cancer. J Gastrointest Oncol 2018;9:495–502.
TRIAD Study Group. The Translating Research Into Action for Diabetes (TRIAD) study: a multicenter study of diabetes in managed care. Diabetes Care 2002;25:386–389.
Keehan SP, Cuckler GA, Poisal JA, et al. National health expenditure projections, 2019-28: expected rebound in prices drives rising spending growth. Health Aff (Millwood) 2020;39:704–714.
Clemens K, Garrison LP Jr, Jones A, et al. Strategic use of pharmacoeconomic research in early drug development and global pricing. Pharmacoeconomics 1993;4:315–322.
Steuten LM, Ramsey SD. Improving early cycle economic evaluation of diagnostic technologies. Expert Rev Pharmacoecon Outcomes Res 2014;14:491–498.
Chen W, Butler RK, Lustigova E, et al. Validation of the enriching new-onset diabetes for pancreatic cancer model in a diverse and integrated healthcare setting. Dig Dis Sci 2021;66:78–87.
Ginde AA, Foianini A, Renner DM, et al. Availability and quality of computed tomography and magnetic resonance imaging equipment in U.S. emergency departments. Acad Emerg Med 2008;15:,780–783.